Soluble CD163

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 72, Issue 1, 2012, Pages 1-13

  Møller, Holger J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CD163; Macrophage; RM3 1 antigen; Scavenger receptor; Serum biomarker

Indexed keywords

CD163 ANTIGEN; HAPTOGLOBIN; HEMOGLOBIN;

ADIPOSE TISSUE; ANTIGEN EXPRESSION; COMORBIDITY; HUMAN; INFLAMMATION; LIVER; LIVER DISEASE; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MONOCYTE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; SEPSIS;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CRITICAL ILLNESS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAUCHER DISEASE; HAPTOGLOBINS; HEMOGLOBINS; HUMANS; INFECTION; INFLAMMATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGES; RECEPTORS, CELL SURFACE; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856041220     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.626868     Document Type: Review

References (145)

1. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69.
2. Gordon S. The macrophage: past, present and future. Eur J Immunol 2007;37(Suppl. 1):S9-17.
3. Maniecki MB, Moller HJ, Moestrup SK, Moller BK. CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes. Immunobiology 2006;211:407-17.
4. Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur J Immunol 1993;23:2320-5. (Pubitemid 23265900)
5. Ritter M, Buechler C, Langmann T, Schmitz G. Genomic organization and chromosomal localization of the human CD163 (M130) gene: a member of the scavenger receptor cysteine-rich superfamily. Biochem Biophys Res Commun 1999;260:466-74. (Pubitemid 29352086)
6. Nielsen MJ, Madsen M, Moller HJ, Moestrup SK. The mac-rophage scavenger receptor CD163: endocytic properties of cytoplasmic tail variants. J Leukoc Biol 2006;79:837-45. (Pubitemid 44835616)
7. Van GH, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010;47:1650-60.
8. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-infl ammatory response. Ann Med 2004;36:347-54. (Pubitemid 39233102)
9. Fabriek BO, Dijkstra CD, van den Berg TK. The mac-rophage scavenger receptor CD163. Immunobiology 2005; 210:153-60.
10. Nielsen MJ, Moller HJ, Moestrup SK. Hemoglobin and heme scavenger receptors. Antioxid Redox Signal 2010;12:261-73.
11. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identifi cation of the haemoglobin scavenger receptor. Nature 2001;409:198-201.
12. Fabriek BO, Polfl iet MM, Vloet RP, van der Schors RC, Ligtenberg AJ, Weaver LK, Geest C, Matsuno K, Moestrup SK, Dijkstra CD, van den Berg TK. The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood 2007;109:5223-9. (Pubitemid 46890540)
13. Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood 2009; 113:887-92.
14. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007;178:8183-94. (Pubitemid 46898091)
15. Sanchez-Torres C, Gomez-Puertas P, Gomez-del-Moral M, Alonso F, Escribano JM, Ezquerra A, Dominguez J. Expression of porcine CD163 on monocytes/macrophages correlates with permissiveness to African swine fever infection. Arch Virol 2003;148:2307-23. (Pubitemid 38038985)
16. Van GH, Van BW, Delputte PL, Nauwynck HJ. Sialoadhesin and CD163 join forces during entry of the porcine reproductive and respiratory syndrome virus. J Gen Virol 2008;89:2943-53.
17. Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identifi cation of the integral membrane protein RM3/1 on human mono-cytes as a glucocorticoid- inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998; 161:1883-90. (Pubitemid 28387610)
18. Van den Heuvel MM, Tensen CP, van As JH, Van den Berg TK, Fluitsma DM, Dijkstra CD, Dö pp EA, Droste A, Van Gaalen FA, Sorg C, Högger P, Beelen RH. Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol 1999;66:858-66. (Pubitemid 29532050)
19. Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000;12:1312-21.
20. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro-and antiinfl ammatory stimuli. J Leukoc Biol 2000;67:97-103. (Pubitemid 30046823)
21. Williams L, Jarai G, Smith A, Finan P. IL-10 expression profi ling in human monocytes. J Leukoc Biol 2002;72: 800-9. (Pubitemid 36277852)
22. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxyge-nase-1 synthesis: antiinfl ammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 2004;94: 119-26. (Pubitemid 38064106)
23. Gleissner CA, Shaked I, Erbel C, Bockler D, Katus HA, Ley K. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res 2010;106:203-11.
24. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61. (Pubitemid 351599757)
25. Boyle JJ, Harrington HA, Piper E, Elderfi eld K, Stark J, Landis RC, Haskard DO. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009;174:1097-108.
26. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, Zlabinger GJ, Stulnig TM. Human adipose tissue macrophages are of an anti-infl ammatory phenotype but capable of excessive pro-infl ammatory mediator production. Int J Obes (Lond) 2007;31:1420-8. (Pubitemid 47339934)
27. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L. Identifi cation of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007;109: 5276-85. (Pubitemid 46890548)
28. Maniecki MB, Etzerodt A, Moestrup SK, Moller HJ, Grav-ersen JH. Comparative assessment of the recognition of domain-specifi c CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. Immunobiology 2011; 216:882-90.
29. Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-MAC3: new monoclonal antibody that defi nes human monocyte/macrophage differentiation antigen. J Clin Pathol 1991;44:936-45.
30. Zwadlo G, Voegeli R, Osthoff KS, Sorg C. A monoclonal antibody to a novel differentiation antigen on human mac-rophages associated with the down-regulatory phase of the infl ammatory process. Exp Cell Biol 1987;55:295-304. (Pubitemid 18087127)
31. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005;29:617-24. (Pubitemid 40577871)
32. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identifi cation of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002;99: 378-80. (Pubitemid 34533008)
33. Sulahian TH, Hintz KA, Wardwell K, Guyre PM. Development of an ELISA to measure soluble CD163 in biological fl uids. J Immunol Methods 2001;252:25-31. (Pubitemid 32382087)
34. Moller HJ, Nielsen MJ, Maniecki MB, Madsen M, Moestrup SK. Soluble macrophage-derived CD163: a homogenous ectodomain protein with a dissociable haptoglobin-hemo-globin binding. Immunobiology 2010;215:406-12.
35. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 1999;256:110-3. (Pubitemid 29298926)
36. Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 2002;72: 711-7. (Pubitemid 36277842)
37. Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Hogger P, Guyre PM, Nagase H, Matsuyama T. Elevated levels of soluble CD163 in sera and fl uids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 2002;130:156-61.
38. Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK. Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 2010;88:1201-5.
39. Reiss K, Saftig P. The'a disintegrin and metalloprotease'(ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 2009;20:126-37.
40. Moreno JA, Ortega-Gómez A, Delbosc S, Beaufort N, Sorbets E, Louedec L, Esposito-Farèse M, Tubach F, Nicoletti A, Steg PG, Michel JB, Feldman L, Meilhac O. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J 2011; In press.
41. Weaver LK, Hintz-Goldstein KA, Pioli PA, Wardwell K, Qureshi N, Vogel SN, Guyre PM. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006;80:26-35. (Pubitemid 44835523)
42. Sulahian TH, Pioli PA, Wardwell K, Guyre PM. Cross-linking of FcgammaR triggers shedding of the hemoglobin-haptoglobin scavenger receptor CD163. J Leukoc Biol 2004;76:271-7. (Pubitemid 38857196)
43. Timmermann M, Hogger P. Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med 2005;39:98-107. (Pubitemid 40733120)
44. Chung S, Kim JE, Park S, Han KS, Kim HK. Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: in vitro effect of thrombin on monocyte CD163 shedding. Thromb Res 2011;127:450-6.
45. Le Gall SM, Maretzky T, Issuree PD, Niu XD, Reiss K, Saftig P, Khokha R, Lundell D, Blobel CP. ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 2010;123:3913-22.
46. Arribas J, Ruiz-Paz S. ADAM 17-regulation of ectodomain shedding. The Adam family of proteases: proteases in biology and disease. The Netherlands: Springer, 2011:171-97.
47. Weaver LK, Pioli PA, Wardwell K, Vogel SN, Guyre PM. Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol 2007;81:663-71. (Pubitemid 46393544)
48. Goldstein JI, Goldstein KA, Wardwell K, Fahrner SL, Goo-nan KE, Cheney MD, Yeager MP, Guyre PM. Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. Atherosclerosis 2003; 170:325-32. (Pubitemid 37377806)
49. Yamazaki H, Ohta K, Tsukiji H, Toma T, Hashida Y, Ishizaki A, Saito T, Arai S, Koizumi S, Yachie A. Corticosteroid enhances heme oxygenase-1 production by circulating monocytes by up-regulating hemoglobin scavenger receptor and amplifying the receptor-mediated uptake of hemoglo-bin-haptoglobin complex. Biochem Biophys Res Commun 2007;358:506-12. (Pubitemid 46755734)
50. Philippidis P, Athanasiou T, Nadra I, Ashrafi an H, Haskard DO, Landis RC, Taylor KM. Anti-infl ammatory haemoglobin scavenging monocytes are induced following coronary artery bypass surgery. Eur J Cardiothorac Surg 2010;37: 1360-6.
51. Kolackova M, Lonsky V, Trojackova Kudlova M, Mandak J, Kunes P, Svitek V, Jankovicova K, Vlaskova D, Andrys C, Krejsek J. Serum level of sCD163, a soluble receptor for hemoglobin, is infl uenced by cardiac surgery. Perfusion 2009;24:263-9.
52. Quimby KR, Greenidge A, Harris A, Landis RC. Phenotypic commitment of monocytes towards a protective hemoglobin scavenging phenotype (CD14(pos)CD163(high) HLA-DR(low))following cardiopulmonary bypass. Cytom-etry B Clin Cytom 2010;78:357-60.
53. Zwadlo-Klarwasser G, Bent S, Haubeck HD, Sorg C, Schmutzler W. Glucocorticoid-induced appearance of the macrophage subtype RM 3/1 in peripheral blood of man. Int Arch Allergy Appl Immunol 1990;91:175-80. (Pubitemid 20167260)
54. Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 2005;63:16-22. (Pubitemid 40096840)
55. Fabriek BO, Møller HJ, Vloet RP, van Winsen LM, Hane-maaijer R, Teunissen CE, Uitdehaag BM, van den Berg TK, Dijkstra CD. Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmu-nol 2007;187:179-86. (Pubitemid 47001547)
56. Hogger P, Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochem Biophys Res Commun 2001;288:841-3. (Pubitemid 33140958)
57. Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett 2002;526:93-6. (Pubitemid 35245699)
58. Timmermann M, Buck F, Sorg C, Hogger P. Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. Immunol Cell Biol 2004;82:479-87. (Pubitemid 39421057)
59. Madsen M, Moller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den BT, Moestrup SK. Molecular characterization of the haptoglobin.hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem 2004;279:51561-7. (Pubitemid 40017906)
60. Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002;62:293-9.
61. NOBIDA biobase. Accessed September 8, 2011 from: http://www.furst.no/ norip/nobida/index.htm
62. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 2011;57:291-7.
63. Moller HJ, Petersen PH, Rejnmark L, Moestrup SK. Biological variation of soluble CD163. Scand J Clin Lab Invest 2003;63:15-21. (Pubitemid 36461145)
64. Baeten D, Moller HJ, Delanghe J, Veys EM, Moestrup SK, De KF. Association of CD163 + macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004;50:1611-23. (Pubitemid 38608084)
65. Funding M, Vorum H, Nexo E, Moestrup SK, Ehlers N, Moller HJ. Soluble CD163 and interleukin-6 are increased in aqueous humour from patients with endothelial rejection of corneal grafts. Acta Ophthalmol Scand 2005;83: 234-9. (Pubitemid 40561835)
66. Bersinger NA, von RS, Wunder DM, Raio L, Dreher E, Mueller MD. PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fl uid of women with endometriosis. Am J Obstet Gynecol 2006;195:103-8. (Pubitemid 43927508)
67. Mistry PK, Cappellini MD, Lukina E, Ozsan H, Mach Pascual S, Rosenbaum H, Helena Solano M, Spigelman Z, Villarrubia J, Watman NP, Massenkeil G. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 2011;86:110-5.
68. Boot RG, van Breemen MJ, Wegdam W, Sprenger RR, de Jong S, Speijer D, Hollak CE, van Dussen L, Hoefsloot HC, Smilde AK, de Koster CG, Vissers JP, Aerts JM. Gaucher disease: a model disorder for biomarker discovery. Expert Rev Proteomics 2009;6:411-9.
69. Moller HJ, de FM, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004;72:135-9. (Pubitemid 38161162)
70. Boven LA, van MM, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122:359-69. (Pubitemid 39145540)
71. Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr 2009;221:278-85.
72. Henter JI, Samuelsson-Horne A, Aric ò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002;100:2367-73.
73. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31. (Pubitemid 44958267)
74. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bächli E, Fehr J, Moller HJ, Moestrup SK, Schaffner A. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specifi c marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005;74:6-10. (Pubitemid 40143680)
75. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffi n T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. The diagnostic signifi cance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idio-pathic arthritis. Arthritis Rheum 2007;56:965-71. (Pubitemid 46399444)
76. Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol 2009;132:10-8.
77. Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 2005;135:299-314. (Pubitemid 40942436)
78. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006; 148:683-6. (Pubitemid 43776910)
79. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010;22:561-6.
80. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34: 1133-8. (Pubitemid 46774861)
81. Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO. Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haema-tol 2006;77:432-6. (Pubitemid 44483947)
82. Gaini S, Koldkjaer OG, Pedersen SS, Pedersen C, Moestrup SK, Moller HJ. Soluble haemoglobin scavenger receptor (sCD163) in patients with suspected community-acquired infections. APMIS 2006;114:103-11. (Pubitemid 43356920)
83. Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 2006;34:2561-6. (Pubitemid 44413053)
84. Knudsen TB, Larsen K, Kristiansen TB, Moller HJ, Tvede M, Eugen-Olsen J, Kronborg G. Diagnostic value of soluble CD163 serum levels in patients suspected of meningitis: comparison with CRP and procalcitonin. Scand J Infect Dis 2007;39:542-53. (Pubitemid 47009163)
85. Carrol ED, Mankhambo LA, Jeffers G, Parker D, Guiver M, Newland P, Banda DL; IPD Study Group, Molyneux EM, Heyderman RS, Molyneux ME, Hart CA. The diagnostic and prognostic accuracy of fi ve markers of serious bacterial infection in Malawian children with signs of severe infection. PLoS One 2009;4:e6621.
86. Piatkowski A, Grieb G, Das R, Bozkurt A, Ulrich D, Pallua N. Soluble CD163: a novel biomarker for the susceptibility to sepsis in severe burn injuries. Indian J Plast Surg 2011; 44:118-24.
87. Gaini S, Pedersen SS, Koldkaer OG, Pedersen C, Moestrup SK, Moller HJ. New immunological serum markers in bacteraemia: anti-infl ammatory soluble CD163, but not proinfl ammatory high mobility group-box 1 protein, is related to prognosis. Clin Exp Immunol 2008;151: 423-31. (Pubitemid 351160736)
88. Weiss M, Schneider EM. Soluble CD163: an age-dependent, anti-infl ammatory biomarker predicting outcome in sepsis. Crit Care Med 2006;34:2682-3. (Pubitemid 44413075)
89. M ø ller HJ, Gr ø nbaek H, Schi ø dt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM; U.S. Acute Liver Failure Study Group. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007;47:671-6.
90. Holland-Fischer P, Grønbæk H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011;60:1389-93.
91. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 2005;40:52-6. (Pubitemid 40796332)
92. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuy-ama T, Onji M. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract 2005;201:379-84. (Pubitemid 40862463)
93. Fonseca JE, Edwards JC, Blades S, Goulding NJ. Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4 +T lymphocyte-rich microen-vironments. Arthritis Rheum 2002;46:1210-6. (Pubitemid 34525827)
94. Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, H ø rslev-Petersen K, J ø rgensen A, Hvid M, Deleuran B. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis. Clin Exp Rheumatol 2011;29:689-92.
95. Ramanathan M, Weinstock-Guttman B, Nguyen LT, Badgett D, Mller C, Patrick K, Brownscheidle C, Jacobs L. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol 2001; 116:213-9. (Pubitemid 32588634)
96. Fabriek BO, Van Haastert ES, Galea I, Polfl iet MM, Döpp ED, Van Den Heuvel MM, Van Den Berg TK, De Groot CJ, Van Der Valk P, Dijkstra CD. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005;51:297-305. (Pubitemid 41532105)
97. Møller HJ, Aerts H, Grønbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, Rejnmark L, Jabbarpour E, Moestrup SK. Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Invest Suppl 2002;237:29-33.
98. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010;12:R128.
99. Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Inoue Y, Ihn H. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int In press.
100. Kowal K, Moller HJ, Dubuske LM, Moestrup SK, Bodzen-ta-Lukaszyk A. Differential expression of monocyte CD163 in single-and dual-asthmatic responders during allergen-induced bronchoconstriction. Clin Exp Allergy 2006;36: 1584-91. (Pubitemid 44902936)
101. Daly A, Walsh C, Feighery C, O'Shea U, Jackson J, Whelan A. Serum levels of soluble CD163 correlate with the infl ammatory process in coeliac disease. Aliment Pharmacol Ther 2006;24:553-9. (Pubitemid 44051332)
102. Bachli EB, Schaer DJ, Walter RB, Fehr J, Schoedon G. Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. J Leu-koc Biol 2006;79:312-8. (Pubitemid 44831163)
103. Walter RB, Bachli EB, Schaer DJ, Ruegg R, Schoedon G. Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. Blood 2003;101:3755-6. (Pubitemid 36857972)
104. Maniecki MB, Hasle H, Friis-Hansen L, Lausen B, Nielsen OJ, Bendix K, Moestrup SK, M ø ller HJ. Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood 2008;112:1510-4.
105. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related infl ammation. J Leukoc Biol 2009;86: 1065-73.
106. Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009;27:3330-7.
107. Kusi KA, Gyan BA, Goka BQ, Dodoo D, Obeng-Adjei G, Troye-Blomberg M, Akanmori BD, Adjimani JP. Levels of soluble CD163 and severity of malaria in children in Ghana. Clin Vaccine Immunol 2008;15:1456-60.
108. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, Moreno PR. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007;101:106-10. (Pubitemid 47094629)
109. Moller HJ, Nielsen MJ, Bartram J, Dick MC, Height SE, Moestrup SK, Rees DC. Soluble CD163 levels in children with sickle cell disease. Br J Haematol 2011;153: 105-10.
110. Korner H, McMorran B, Schluter D, Fromm P. The role of TNF in parasitic diseases: still more questions than answers. Int J Parasitol 2010;40:879-88.
111. Quesniaux VF, Jacobs M, Allie N, Grivennikov S, Nedos-pasov SA, Garcia I, Olleros ML, Shebzukhov Y, Kuprash D, Vasseur V, Rose S, Court N, Vacher R, Ryffel B. TNF in host resistance to tuberculosis infection. Curr Dir Autoim-mun 2010;11:157-79.
112. Knudsen TB, Gustafson P, Kronborg G, Kristiansen TB, Moestrup SK, Nielsen JO, Gomes V, Aaby P, Lisse I, Møller HJ, Eugen-Olsen J. Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verifi ed tuberculosis patients. Clin Microbiol Infect 2005;11:730-5. (Pubitemid 41167339)
113. Le D, V, Herbein G, Rohr O, Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 2010;7:32.
114. Fischer-Smith T, Tedaldi EM, Rappaport J. CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res Hum Retroviruses 2008;24: 417-21. (Pubitemid 351457747)
115. Tippett E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, Jaworowski A, Crowe SM. Differential expression of CD163 on monocyte subsets in healthy and HIV-1 infected individuals. PLoS One 2011;6:e19968.
116. Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, Alvarez X, Kuroda MJ, Williams KC. Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog 2010;6:e1000842.
117. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, Rosenberg ES, Ellis RJ, Williams KC. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011;204: 154-63.
118. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leu-koc Biol 2010;87:589-98.
119. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic infl ammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112: 1821-30. (Pubitemid 38063705)
120. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett 2007;112:61-7. (Pubitemid 47379852)
121. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112: 1796-808. (Pubitemid 38063703)
122. Torres SH, De Sanctis JB, de LB, Hernandez N, Finol HJ. Infl ammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol 2004;181: 419-27. (Pubitemid 38868192)
123. Axelsson J, Møller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimb ü rger O, B á r á ny P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 2006;48:916-25. (Pubitemid 44895371)
124. Sporrer D, Weber M, Wanninger J, Weigert J, Neumeier M, Stögbauer F, Lieberer E, Bala M, Kopp A, Schäffler A, Buechler C. Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity. Eur J Clin Invest 2009;39:671-9.
125. Shakeri-Manesch S, Zeyda M, Huber J, Ludvik B, Prager G, Stulnig TM. Diminished upregulation of visceral adipose heme oxygenase-1 correlates with waist-to-hip ratio and insulin resistance. Int J Obes (Lond) 2009;33: 1257-64.
126. Paidas MJ, Ku DH, Davis B, Lockwood CJ, Arkel YS. Soluble monocyte cluster domain 163, a new global marker of anti-infl ammatory response, is elevated in the fi rst trimester of pregnancy. J Thromb Haemost 2004;2: 1009-10. (Pubitemid 40185751)
127. Vogel I, Goepfert AR, Moller HJ, Cliver S, Thorsen P, Andrews W W. Early mid-trimester serum relaxin, soluble CD163, and cervical length in women at high risk for preterm delivery. Am J Obstet Gynecol 2006;195: 208-14. (Pubitemid 43927507)
128. Vogel I, Grove J, Thorsen P, Moestrup SK, Uldbjerg N, Moller HJ. Preterm delivery predicted by soluble CD163 and CRP in women with symptoms of preterm delivery. BJOG 2005;112:737-42. (Pubitemid 40852841)
129. Kronborg CS, Knudsen UB, Moestrup SK, Allen J, Vittinghus E, Moller HJ. Serum markers of macrophage activation in pre-eclampsia: no predictive value of soluble CD163 and neopterin. Acta Obstet Gynecol Scand 2007;86:1041-6. (Pubitemid 47345778)
130. McDonald SD, Han Z, Mulla S, Beyene J. Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses. BMJ 2010;341:c3428.
131. Jee BC, Suh CS, Kim SH, Moon SY. Serum soluble CD163 and interleukin-6 levels in women with ovarian endometriomas. Gynecol Obstet Invest 2008;66:47-52. (Pubitemid 352009131)
132. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol 2009;7:234-43.
133. Gustafson B. Adipose tissue, infl ammation and atherosclerosis. J Atheroscler Thromb 2010;17:332-41.
134. Ijäs P, Nuotio K, Saksi J, Soinne L, Saimanen E, Karjalain-en-Lindsberg ML, Salonen O, Sarna S, Tuimala J, Kovanen PT, Kaste M, Lindsberg PJ. Microarray analysis reveals overexpression of CD163 and HO-1 in symptomatic carotid plaques. Arterioscler Thromb Vasc Biol 2007;27: 154-60. (Pubitemid 46360393)
135. Yunoki K, Naruko T, Komatsu R, Ehara S, Shirai N, Sug-ioka K, Nakagawa M, Kitabayashi C, Ikura Y, Itoh A, Kusano K, Ohe T, Haze K, Becker AE, Ueda M. Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes. Eur Heart J 2009;30:1844-52.
136. Agardh HE, Folkersen L, Ekstrand J, Marcus D, Sweden-borg J, Hedin U, Gabrielsen A, Paulsson-Berne G. Expression of fatty acid-binding protein 4/aP2
137. Levy AP, Moreno PR. Intraplaque hemorrhage. Curr Mol Med 2006;6:479-88.
138. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010;30:1253-62.
139. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Krithari-des L. The monocytic lineage specifi c soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006;184:342-7. (Pubitemid 43049718)
140. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009;207:103-10.
141. Sanak M, Plutecka H, Szczeklik W, Piwowarska W, Rostoff P, Szczeklik A. Functional promoter polymorphism of cyclooxygenase-2 modulates the infl ammatory response in stable coronary heart disease. Pol Arch Med Wewn 2010;120:82-8.
142. Willemsen HM, van der Horst IC, Nieuwland W, Slart RJ, Zeebregts CJ, de Boef E, Schuitemaker JH, Zijlstra F, Tio RA. The diagnostic value of soluble CD163 in patients presenting with chest pain. Clin Biochem 2009;42: 1662-6.
143. Terkelsen CJ, Oxvig C, Nørgaard BL, Glerup S, Poulsen TS, Lassen JF, Møller HJ, Thuesen L, Falk E, Nielsen TT, Andersen HR. Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myo-cardial infarction patients and potential signifi cance of concomitant heparin administration. Am J Cardiol 2009; 103:29-35.
144. Rahman SH, Menon KV, Holmfi eld JH, McMahon MJ, Guillou J P. Serum macrophage migration inhibitory factor is an early marker of pancreatic necrosis in acute pancreatitis. Ann Surg 2007;245:282-9. (Pubitemid 46148488)
145. Simoni J, Simoni G, Griswold JA, Moeller JF, Tsikouris JP, Khanna A, Roongsritong C, Wesson DE. Role of free hemoglobin in 8-iso prostaglandin F2-alpha synthesis in chronic renal failure and its impact on CD163-Hb scavenger receptor and on coronary artery endothelium. ASAIO J 2006;52:652-61. (Pubitemid 44784567)